{"doi":"10.1007\/s00280-007-0611-8","coreId":"197257","oai":"oai:lra.le.ac.uk:2381\/9494","identifiers":["oai:lra.le.ac.uk:2381\/9494","10.1007\/s00280-007-0611-8"],"title":"Consumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma (TAg) mouse","authors":["Verschoyle, Richard D.","Brown, Karen","Steward, William P.","Gescher, Andreas J."],"enrichments":{"references":[],"documentType":{"type":null}},"contributors":[],"datePublished":"2008-07","abstract":"This paper was published as Cancer Chemotherapy and Pharmacology, 2008, 62 (2), pp. 369-372.  It is available from http:\/\/www.springerlink.com\/content\/6320020g83886223\/.  DOI: 10.1007\/s00280-007-0611-8Metadata only entrySilibinin is a flavonolignan extracted from milk thistle with cancer chemopreventive activity in preclinical models of prostate and colorectal cancer. A milk thistle extract, of which silibin is a major component, has recently been shown to exacerbate mammary carcinogenesis in two rodent models. We tested the hypothesis that consumption of silibinin or silipide, a silibinin formulation with pharmaceutical properties superior to the unformulated agent, affect breast cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma mouse model. Mice received silibinin or silipide (0.2% silibinin equivalents) with their diet from weaning, and tumour development was monitored by weekly palpation and the number and weight of neoplasms at the end of the experiment. Intervention neither promoted, nor interfered with, tumour development. The result suggests that promotion of carcinogenesis is not a feature of silibinin consistent across rodent models of mammary carcinogenesis","downloadUrl":"","fullTextIdentifier":null,"pdfHashValue":null,"publisher":"Springer Verlag","rawRecordXml":"<record><header><identifier>\n        \n            \n                oai:lra.le.ac.uk:2381\/9494<\/identifier><datestamp>\n                2011-06-29T15:26:20Z<\/datestamp><setSpec>\n                com_2381_162<\/setSpec><setSpec>\n                com_2381_9550<\/setSpec><setSpec>\n                col_2381_163<\/setSpec>\n            <\/header><metadata><oai_dc:dc xmlns:oai_dc=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/\" xmlns:dc=\"http:\/\/purl.org\/dc\/elements\/1.1\/\" xmlns:doc=\"http:\/\/www.lyncode.com\/xoai\" xmlns:xsi=\"http:\/\/www.w3.org\/2001\/XMLSchema-instance\" xsi:schemaLocation=\"http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc\/ http:\/\/www.openarchives.org\/OAI\/2.0\/oai_dc.xsd\" ><dc:title>\n            \nConsumption of silibinin, a flavonolignan from milk thistle, and mammary cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma (TAg) mouse<\/dc:title><dc:creator>\nVerschoyle, Richard D.<\/dc:creator><dc:creator>\nBrown, Karen<\/dc:creator><dc:creator>\nSteward, William P.<\/dc:creator><dc:creator>\nGescher, Andreas J.<\/dc:creator><dc:subject>\nChemoprevention<\/dc:subject><dc:subject>\nPreclinical models<\/dc:subject><dc:subject>\nSilibinin<\/dc:subject><dc:subject>\nBreast cancer<\/dc:subject><dc:description>\nThis paper was published as Cancer Chemotherapy and Pharmacology, 2008, 62 (2), pp. 369-372.  It is available from http:\/\/www.springerlink.com\/content\/6320020g83886223\/.  DOI: 10.1007\/s00280-007-0611-8<\/dc:description><dc:description>\nMetadata only entry<\/dc:description><dc:description>\nSilibinin is a flavonolignan extracted from milk thistle with cancer chemopreventive activity in preclinical models of prostate and colorectal cancer. A milk thistle extract, of which silibin is a major component, has recently been shown to exacerbate mammary carcinogenesis in two rodent models. We tested the hypothesis that consumption of silibinin or silipide, a silibinin formulation with pharmaceutical properties superior to the unformulated agent, affect breast cancer development in the C3(1) SV40 T,t antigen transgenic multiple mammary adenocarcinoma mouse model. Mice received silibinin or silipide (0.2% silibinin equivalents) with their diet from weaning, and tumour development was monitored by weekly palpation and the number and weight of neoplasms at the end of the experiment. Intervention neither promoted, nor interfered with, tumour development. The result suggests that promotion of carcinogenesis is not a feature of silibinin consistent across rodent models of mammary carcinogenesis.<\/dc:description><dc:date>\n2011-06-29T15:23:43Z<\/dc:date><dc:date>\n2011-06-29T15:23:43Z<\/dc:date><dc:date>\n2008-07<\/dc:date><dc:type>\nArticle<\/dc:type><dc:identifier>\nCancer Chemotherapy and Pharmacology, 2008, 62 (2), pp. 369-372.<\/dc:identifier><dc:identifier>\n0344-5704<\/dc:identifier><dc:identifier>\nhttp:\/\/dx.doi.org\/10.1007\/s00280-007-0611-8<\/dc:identifier><dc:identifier>\nhttp:\/\/www.springerlink.com\/content\/6320020g83886223\/<\/dc:identifier><dc:identifier>\nhttp:\/\/hdl.handle.net\/2381\/9494<\/dc:identifier><dc:language>\nen<\/dc:language><dc:format>\nMetadata<\/dc:format><dc:publisher>\nSpringer Verlag<\/dc:publisher>\n<\/oai_dc:dc>\n<\/metadata>\n        <\/record>","journals":[{"title":null,"identifiers":["0344-5704","issn:0344-5704"]}],"language":null,"relations":[],"year":2008,"topics":["Chemoprevention","Preclinical models","Silibinin","Breast cancer"],"subject":["Article"],"fullText":null}